Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

Inclusion Criteria

• •1. Able to understand and sign the Informed Consent Form.
• •2. Pathology confirmed epithelial Ovarian/Fallopian Tube/Primary Peritoneal carcinomatosis.
• •3. For ovarian/peritoneal carcinoma: Platinum- resistant or platinum refractory disease (platinum-resistant disease is defined as disease-progression within 6 months of completion of prior platinum containing regimen, whereas platinum refractory disease is defined as disease progression while on platinum containing regimen or within 3 months from first line, adjuvant chemotherapy).
• •4. Received and exhausted standard of care therapies for recurrent ovarian cancer and further chemotherapy lines have no proven added value. (For platinum resistant disease, received no more than 3 prior chemotherapy lines, whereas for platinum refractory disease received no more than 2 previous chemotherapy lines).
• •5. Patients must have at least one lesion that is resectable for TIL generation.
• •6. Have measurable disease per RECIST 1.1.
• •7. Patients with one or more brain metastases less than 1 cm each, and any patients with 1 or 2 brain metastases greater than 1 cm must have been treated and stable for 6 weeks.
• •8. Greater than or equal to 18 years of age.
• •9. For Patients with child bearing potential, willing to practice birth control from the start of chemotherapy until 120 days after release from the hospital.
• •10. Life expectancy of greater than three months
• •11. Performance status of ECOG 0 or 1
• •12. Adequate organ function defined by lab test results:
• •Hematology:
• •Absolute neutrophil count greater than 1000/mm3 without support of filgrastim Normal WBC greater than 3000/mm3. Hemoglobin greater than 9.0 g/dL Platelet count greater than 100,000/mm3
• •Serology:
• •Seronegative for HIV antibody. Seronegative for Hepatitis B or Hepatitis C (patients who recovered from previous infection and have no detected HBSAg or HCV RNA are allowed).
• •Chemistry:
• •Serum ALT/AST less than three times the upper limit of normal (ULN). Serum creatinine less than or equal to 1.6 mg/dL Total bilirubin no more than 1.5 times the ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3 mg/dL.
• •13. Negative pregnancy test in women of child bearing potential.
• •14. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). Patients may have undergone minor surgical procedures with the past 3 weeks, as long as all toxicities have recovered to grade 1 or less.
• •Note: As described in the Study Population section in the synopsis, before entering the trial, the medical team will present other available experimental therapies to the patient for her consideration.